Skip to main content
Premium Trial:

Request an Annual Quote

PrecisionLife Acquires Danish Collaborator GenoKey

NEW YORK — PrecisionLife said on Wednesday that it has acquired Danish genomic analytics firm GenoKey.

PrecisionLife said that it has worked with GenoKey, which is now a wholly owned subsidiary, on the development of the technology underlying its flagship artificial intelligence-driven bioinformatics platform for biomarker discovery and drug target validation. 

"The acquisition of GenoKey solidifies a long-term, highly productive collaboration around core IP and positions PrecisionLife for its next round of investment and growth," PrecisionLife CEO Steve Gardner said in a statement.

Following the acquisition, UK-based PrecisionLife said it will keep its core platform development operations at GenoKey's site in Denmark, which it plans to expand with additional hires. GenoKey Cofounder and Chairman Hans-Christian Brahe Møller will join the board of the new subsidiary.

Financial and other terms of the acquisition were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.